FibroGen, Inc. (NASDAQ:FGEN) Director Purchases $87,500.00 in Stock

FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck bought 250,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The stock was bought at an average cost of $0.35 per share, with a total value of $87,500.00. Following the completion of the acquisition, the director now owns 323,722 shares in the company, valued at $113,302.70. This represents a 339.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

FibroGen Price Performance

Shares of FGEN stock traded up $0.04 during trading hours on Monday, hitting $0.35. 600,885 shares of the company’s stock were exchanged, compared to its average volume of 2,325,364. The stock’s 50-day moving average is $0.49 and its 200-day moving average is $0.43. FibroGen, Inc. has a 52 week low of $0.18 and a 52 week high of $2.80. The stock has a market cap of $35.62 million, a price-to-earnings ratio of -0.29 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $24.91 million. Equities research analysts forecast that FibroGen, Inc. will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Mackenzie Financial Corp raised its stake in FibroGen by 416.6% during the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 441,083 shares during the period. Velan Capital Investment Management LP acquired a new position in FibroGen in the fourth quarter valued at about $42,000. Squarepoint Ops LLC bought a new stake in shares of FibroGen in the fourth quarter worth about $205,000. Two Sigma Investments LP raised its position in shares of FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 98,888 shares during the period. Finally, Two Sigma Advisers LP lifted its holdings in shares of FibroGen by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after purchasing an additional 135,600 shares in the last quarter. 72.71% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. StockNews.com initiated coverage on shares of FibroGen in a research report on Saturday. They set a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Tuesday, March 18th.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.